Pharma Pulse 6/3/25: Preparing for the Pharma C-Suite; America’s Vanishing Scientific Research Workforce is a Threat to Public Health
Preparing for the Pharma C-Suite
In a Pharmaceutical Executive feature, Aileen Fernandes, Chief Business Officer at Arcellx, reflects on how her early roles at Morgan Stanley and Deloitte Consulting, combined with strategic career decisions and authentic leadership development, prepared her for biotechnology C-suite success and offers MBA students key advice on culture fit, building healthcare connections, and leveraging their education to shape fulfilling leadership paths.
America’s Vanishing Scientific Research Workforce is a Threat to Public Health
In an article for Applied Clinical Trials, Igna Rose, CEO, Reference Medicine, warns that the United States’ dwindling scientific research workforce—driven by burnout, eroded public trust, reduced funding, and restrictive immigration policies—poses a dire threat to public health and medical progress, suggesting urgent, systemic action to rebuild the talent pipeline and restore the sustainability and appeal of lab careers.
The MAHA agenda won’t include expanding GLP-1 coverage — for now
The recent decision not to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs underscores ongoing political, economic, and regulatory tensions, as advocates highlight the long-term health and cost benefits of broader access while the current administration prioritizes cost containment and lifestyle interventions over medication-first approaches.
NLA 2025: Bempedoic Acid Supports ASCVD Prevention and LDL-C Reduction
At the 2025 NLA Scientific Sessions, Dr. Steven Nissen highlighted bempedoic acid as an effective LDL-C–lowering option for statin-intolerant patients, supported by CLEAR trial data demonstrating cardiovascular benefits and suitability for individualized risk management.
Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment
Diakonos Oncology has raised $20 million through a private SAFE round to advance its Phase II glioblastoma trial of dubodencel, an autologous dendritic cell therapy, and expand into new indications like refractory melanoma.
